Free Trial

Danaher (NYSE:DHR) Earns Hold (C-) Rating from Weiss Ratings

Danaher logo with Medical background

Key Points

  • Danaher has received a "hold (C-)" rating from Weiss Ratings, along with a consensus rating of "Moderate Buy" from 17 analysts and a current average target price of $244.60.
  • The company's stock price recently traded at $205.13, with a 52-week range of $171.00 to $279.41, and reported a revenue of $5.94 billion for the latest quarter, exceeding analyst estimates.
  • Insider selling was reported, with a director selling 2,778 shares at an average price of $211.06, resulting in an 11.81% decrease in their ownership of the stock.
  • MarketBeat previews the top five stocks to own by November 1st.

Danaher (NYSE:DHR - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the stock. UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Guggenheim reissued a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Evercore ISI increased their price objective on shares of Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Seventeen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $244.60.

Check Out Our Latest Report on DHR

Danaher Price Performance

NYSE DHR traded down $3.64 on Wednesday, hitting $205.13. The stock had a trading volume of 5,089,510 shares, compared to its average volume of 5,150,140. Danaher has a 52-week low of $171.00 and a 52-week high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $146.88 billion, a price-to-earnings ratio of 43.64, a price-to-earnings-growth ratio of 2.97 and a beta of 0.77. The firm has a 50-day moving average of $200.41 and a 200-day moving average of $197.38.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the firm earned $1.72 EPS. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts expect that Danaher will post 7.63 EPS for the current year.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 11.10% of the company's stock.

Institutional Trading of Danaher

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate's stock valued at $12,004,424,000 after acquiring an additional 788,499 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after buying an additional 612,154 shares during the last quarter. Geode Capital Management LLC boosted its stake in Danaher by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate's stock worth $2,697,800,000 after buying an additional 81,670 shares during the last quarter. Norges Bank acquired a new stake in Danaher in the 2nd quarter worth about $1,979,503,000. Finally, Bank of New York Mellon Corp boosted its stake in Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after buying an additional 194,466 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Analyst Recommendations for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.